<div id="readability-page-1"><div>By Katherine Hamilton Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone. Sogroya is now indicated for kids aged 2.5 years and older with disorders affecting their height, including idiopathic short stature, short stature born small for gestational age, or growth failure associated with Noonan Syndrome. It is also indicated for children of the same age group and adults with growth hormone deficiency. Sogroya is a once-weekly injection which comes in 5 mg, 10 mg and 15 mg dosages. Novo Nordisk has been studying Sogroya as a way for people with growth disorders to avoid daily injections. In a study, Sogroya demonstrated non-inferiority compared with daily somatropin and growth hormone dosages. Novo Nordisk also submitted a supplemental application for Sogroya's approval in the U.S. for Turner Syndrome. A decision is expected later this year, the company said. Write to Katherine Hamilton at katherine.hamilton@wsj.com (END) Dow Jones Newswires02-27-26 1633ET</div></div>

諾和諾德公司

諾和諾德公司已獲得 FDA 批准，將 Sogroya（生長激素治療）用於 2.5 歲及以上兒童的身高相關疾病的新適應症，包括特發性矮小和生長激素缺乏症。Sogroya 是一種每週注射一次的藥物，提供 5 毫克、10 毫克和 15 毫克的劑量，旨在減少每日注射的需求。該公司還在等待對今年晚些時候申請的特納綜合症補充申請的決定

FDA 批准諾和諾德公司的生長障礙治療藥物用於新的患者羣體